TIDMMEDG 
 
RNS Number : 1108T 
Medgenics Inc 
22 September 2010 
 

 
 
                                Medgenics, Inc. 
                         ('Medgenics' or the 'Company') 
 
                               Fundraising update 
22 September 2010 
 
Medgenics, Inc. (AIM: MEDG, MEDU), the company that has developed a novel 
technology for the manufacture and delivery of therapeutic proteins continuously 
in patients using their own tissue, is pleased to announce that, further to the 
announcements dated 24 August 2010 and 15 September 2010, it has now received 
firm commitments, on the terms announced on 24 August 2010, to subscribe for the 
proposed new convertible debentures in excess of the $3 million originally 
envisaged. 
 
The Directors expect to raise $4 million through this debenture issue by the end 
of this week. The Company will announce the final result of the debenture round 
at such time. 
 
For further information, contact: 
 
+--------------------------------------+------------------------+ 
| Medgenics, Inc.                      | Phone: +972 4 902 8900 | 
| Dr. Andrew L. Pearlman               |                        | 
|                                      |                        | 
+--------------------------------------+------------------------+ 
| Religare Capital Markets (Nominated  | Phone: +44 207 444     | 
| Adviser)                             | 0800                   | 
| James Pinner                         |                        | 
| Derek Crowhurst                      |                        | 
|                                      |                        | 
+--------------------------------------+------------------------+ 
| SVS Securities plc (Joint Broker)    | Phone: +44 207 638     | 
| Ian Callaway                         | 5600                   | 
|                                      |                        | 
+--------------------------------------+------------------------+ 
| Nomura Code Securities PLC (Joint    | Phone: +44 207 776     | 
| Broker)                              | 1219                   | 
| Jon Senior                           |                        | 
|                                      |                        | 
+--------------------------------------+------------------------+ 
| De Facto Communications              | Phone: +44 20 7861     | 
| Mike Wort                            | 3838                   | 
| Anna Dunphy                          |                        | 
|                                      |                        | 
+--------------------------------------+------------------------+ 
| Grayling (Investment Relations - US) | Phone:  +1 646 284     | 
| Leslie Wolf-Creutzfeldt              | 9472                   | 
+--------------------------------------+------------------------+ 
Notes to Editors: 
About Medgenics: 
Medgenics is a commercial-stage biopharmaceutical company developing its unique 
tissue-based Biopump platform technology to provide sustained-action protein 
therapy for the treatment of a range of chronic diseases. The first revenue 
generating commercial deal with a well-known multinational pharmaceutical 
company was negotiated in late 2009 and we look forward to generating additional 
deals to further commercialise the Biopump platform technology. 
For more information please visit: www.medgenics.com 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 MSCUUSRRRAAKUAR
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Medgenics(Regs) Charts.
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Medgenics(Regs) Charts.